Simultaneous integrated boost radiotherapy has been investigated in some malignant tumors and appears to be safe and feasible. However, Hypofractionation with simultaneous integrated boost has been investigating in breast cancer. Investigators initiated this phase II prospective trial to analyse acute toxicity of hypofractionation with simultaneous integrated boost in patients with early breast cancer.
Hypofractionated radiotherapy of the breast 15 × 2.70 Gy with simultaneous integrated boost to the tumor bed (total dose within the boost volume 15 × 3.20 Gy)
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
35
Hypofractionation with simultaneous integrated boost
Beijing Shijitan Hospital
Beijing, China
Acute Toxicity
Acute skin radiogenic toxicity grade II or higher according to NCI-CTCAE
Time frame: 6 months
Feasibility of the radiation plan
Dose constraints Dmean lung \< 10 Gy; Dmean heart \< 5 Gy, Dmedian contralateral breast \< 4Gy
Time frame: 19 days
other acute Toxicity
All dimensions of NCI-CTCAE/RTOG
Time frame: 0-6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.